TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$256 Million


Initial Public Offering

Bookrunner, June 2018

Tricida is a clinical-stage specialty biopharmaceutical company focused on the development of TRC101, a non-absorbed polymer drug for the treatment of metabolic acidosis (MA) in Chronic Kidney Disease (CKD) patients. MA is a chronic condition caused by CKD that also accelerates the progression of kidney deterioration. There are currently no FDA approved treatments for MA and unapproved treatments, such as sodium bicarbonate, introduce significant amounts of sodium to the MA patients who already suffer from sodium sensitive comorbid conditions.  TRC101 is designed to treat MA by binding to and removing acid from the GI tract and does so without affecting serum parameters, such as sodium. In March 2019, Tricida announced positive topline results from the Phase III study of TRC101. Based on the Phase III results, the Company is seeking approval of TRC101 through the FDA’s Accelerated Approval Program. The Company anticipates filing an NDA in 2H 2019 and is enrolling the VALOR-CKD confirmatory postmarketing trial to support the commercial launch.